City File: Wellcome gains from sector review
IF THERE is a re-rating of the drugs sector, which optimists expect once Bill Clinton elaborates on his healthcare reforms, Wellcome is bound to be a big beneficiary.
Wellcome is not suffering, like some of its rivals, from the general mood to cut healthcare costs, thanks to its specialisation in anti-viral drugs, such as the Aids treatment, Retrovir, and the herpes drug, Zovirax.
Its half-year results, due on Thursday, will show profits rising by a third to about pounds 320m and, while most of its rivals are suffering from a slack first quarter, Wellcome is expected to show that it is powering on.
At 886p, the company's shares trade on 18.5 times this year's expected earnings. This is cheap on a year's view.
(Graph omitted)
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies